

# Fernando Aranda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6876155/publications.pdf>

Version: 2024-02-01

63  
papers

3,984  
citations

172207

29  
h-index

143772

57  
g-index

64  
all docs

64  
docs citations

64  
times ranked

8028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
2	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	7.7	410
3	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
4	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
5	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2014, 3, e957994.	2.1	223
6	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27878.	2.1	134
7	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1008814.	2.1	102
8	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e26621.	2.1	101
9	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27297.	2.1	99
10	Trial Watch”Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740.	2.1	88
11	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e29179.	2.1	76
12	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	5.8	71
13	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27048.	2.1	69
14	CD6 modulates thymocyte selection and peripheral T cell homeostasis. <i>Journal of Experimental Medicine</i> , 2016, 213, 1387-1397.	4.2	68
15	Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. <i>Oncogene</i> , 2015, 34, 3053-3062.	2.6	67
16	Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. <i>Cell Metabolism</i> , 2019, 30, 754-767.e9.	7.2	67
17	Induction of Monocyte Chemoattractant Protein-1 and Interleukin-10 by TGF $\beta$ 1 in Melanoma Enhances Tumor Infiltration and Immunosuppression. <i>Cancer Research</i> , 2011, 71, 812-821.	0.4	65
18	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmmunology</i> , 2016, 5, e1214790.	2.1	64

#	ARTICLE	IF	CITATIONS
19	Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors. <i>Cancer Research</i> , 2011, 71, 3214-3224.	0.4	63
20	Peptide inhibitors of transforming growth factor- $\beta$ enhance the efficacy of antitumor immunotherapy. <i>International Journal of Cancer</i> , 2009, 125, 2614-2623.	2.3	62
21	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolmunology</i> , 2014, 3, e963424.	2.1	62
22	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolmunology</i> , 2017, 6, e1373237.	2.1	62
23	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>Oncolmunology</i> , 2016, 5, e1115942.	2.1	52
24	Trial watch. <i>Oncolmunology</i> , 2014, 3, e29030.	2.1	51
25	Myeloid-derived cells are key targets of tumor immunotherapy. <i>Oncolmunology</i> , 2014, 3, e28398.	2.1	47
26	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolmunology</i> , 2016, 5, e1149674.	2.1	46
27	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolmunology</i> , 2018, 7, e1433982.	2.1	38
28	Impact of myeloid cells on the efficacy of anticancer chemotherapy. <i>Current Opinion in Immunology</i> , 2014, 30, 24-31.	2.4	35
29	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
30	Trial Watch. <i>Oncolmunology</i> , 2014, 3, e28344.	2.1	31
31	Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmunology</i> , 2015, 4, e1046673.	2.1	29
32	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmunology</i> , 2015, 4, e1026531.	2.1	26
33	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR $\beta$ 1. <i>European Journal of Immunology</i> , 2017, 47, 1108-1118.	1.6	23
34	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
35	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. <i>Journal of Hepatology</i> , 2015, 63, 329-336.	1.8	21
36	CD5 as a Target for Immune-Based Therapies. <i>Critical Reviews in Immunology</i> , 2015, 35, 85-115.	1.0	20

#	ARTICLE	IF	CITATIONS
37	Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. <i>Oncolimmunology</i> , 2016, 5, e1075113.	2.1	20
38	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. <i>Cellular and Molecular Immunology</i> , 2018, 15, 898-906.	4.8	17
39	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. <i>Oncolimmunology</i> , 2014, 3, e955685.	2.1	16
40	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. <i>International Journal of Cancer</i> , 2016, 139, 1297-1302.	2.3	14
41	Immune effectors responsible for the elimination of hyperploid cancer cells. <i>Oncolimmunology</i> , 2018, 7, e1463947.	2.1	14
42	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1074-1083.	1.3	14
43	Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases. <i>PLoS ONE</i> , 2014, 9, e96799.	1.1	12
44	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. <i>Frontiers in Immunology</i> , 2017, 8, 594.	2.2	12
45	Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents. <i>Cells</i> , 2020, 9, 2589.	1.8	12
46	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. <i>Cancers</i> , 2021, 13, 963.	1.7	12
47	Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. <i>Oncolimmunology</i> , 2016, 5, e1196309.	2.1	10
48	Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	10
49	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
50	Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. <i>Oncotarget</i> , 2017, 8, 5247-5255.	0.8	10
51	Gut microbiota metabolites for sweetening type I diabetes. <i>Cellular and Molecular Immunology</i> , 2018, 15, 92-95.	4.8	9
52	Immunomodulatory effects of soluble CD5 on experimental tumor models. <i>Oncotarget</i> , 2017, 8, 108156-108169.	0.8	8
53	Multifaceted effects of soluble human CD6 in experimental cancer models. , 2020, 8, e000172.		7
54	Overcoming the limitations of cytokines to improve cancer therapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 107-141.	1.6	7

#	ARTICLE	IF	CITATIONS
55	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN- $\beta$ . <i>Journal of Immunology</i> , 2019, 203, 696-704.	0.4	6
56	Production and use of adeno-associated virus vectors as tools for cancer immunotherapy. <i>Methods in Enzymology</i> , 2020, 635, 185-203.	0.4	3
57	Transforming growth factor beta (TGF- $\beta$ ) activity in immuno-oncology studies. <i>Methods in Enzymology</i> , 2020, 636, 129-172.	0.4	3
58	Firefighters for the Wrong Type of Inflammation in Tumors. <i>Cancer Discovery</i> , 2021, 11, 2372-2374.	7.7	3
59	Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. <i>Oncolmmunology</i> , 2022, 11, .	2.1	3
60	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. <i>Frontiers in Immunology</i> , 2020, 11, 620283.	2.2	2
61	Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution. <i>Prostate</i> , 2022, 82, 1331-1337.	1.2	2
62	Transgenic Tumor Models for Evaluating CAR Tâ€Cell Immunotherapies. <i>Current Protocols in Pharmacology</i> , 2019, 86, e66.	4.0	0
63	Revisiting Intracavitary Immunotherapy of Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1993-1995.	3.2	0